Conference Roundup

Inhaled Nitric Oxide Improves Physical Activity Iin Patients with Pulmonary Fibrosis At-risk for Pulmonary Hypertension

Posted on

Improvements in physical activity after treatment with inhaled nitric oxide was noted in patients with pulmonary fibrosis at-risk for pulmonary hypertension, according to study results presented by Steven D. Nathan, MD, FCCP, advanced lung disease and lung transplant program, Inova Fairfax Hospital at the CHEST Annual Meeting.

In the randomized, double-blind, placebo-controlled study, patients at risk for pulmonary hypertension associated with pulmonary fibrosis on long-term oxygen therapy were given pulsed inhaled nitric oxide at 30 µg/kg based on ideal body weight per hour (n = 23) or placebo (n = 18). According to the presentation, patients had a range of pulmonary fibrosing interstitial lung diseases.

A medical grade actigraph was worn on the wrist during physical activity. Patients experienced a placebo-corrected 34% improvement in physical activity with inhaled nitric oxide during the treatment period.


Nathan SD. Late Breaking Abstracts. Presented at: CHEST Annual Meeting; October 19-23, 2019; New Orleans.

Related Articles
New Opsumit (macitentan) Data Show Initial Combination Therapy with Tadalafil Improved Hemodynamic Clinical and Functional Parameters in Patients with Pulmonary Arterial Hypertension
May 31, 2020
FDA Approves First Treatment for Chronic Fibrosing ILDs with Progressive Phenotype
Mar 16, 2020
AAAI Cancels Annual Meeting
Mar 14, 2020